PER-006-08未知未知
A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin´s Lymphomas
ELI LILLY AND COMPANY,0 个研究点目标入组 0 人开始时间: 2008年2月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •> 18 years old
- •Relapse or progression, during or after receiving at least 1 chemotherapy regimen for T-cell and B-cell lymphoma or 2 previous chemotherapy regimens for aggressive B-cell lymphoma or for whom it is not available a standard treatment that is Intolerant to some standard therapy.
- •Samples of the original tumor biopsy or the most recent biopsy should be available and the disease should be confirmed by a local pathologist; Enrollment is based on the evaluation of the local pathologist, however, an independent centralized pathological evaluation can be performed on all patient samples.
- •Have measurable injuries
- •Having recovered from previous chemotherapy
- •Have an operating status of 0, 1 or 2 on the ECOG scale (Annex of protocol S057.8)
- •Have a life expectancy of at least 12 weeks
- •Have signed the informed consent
- •Female and male patients with reproductive potential should use an approved contraceptive method, if appropriate (eg [IUD] intrauterine device, oral contraceptive, barrier device) during and 3 months after discontinuation of the study treatment. Women with the birth potential must have a negative serum pregnancy test within 3 days before receiving the first dose of the study medication
- •Have adequate organ functions
排除标准
- •That they have received a drug within the last 30 days, which has not been authorized by a regulatory entity during the time of inclusion in the study.
- •Have a history of lymphoma with CNS metastases, except for patients with primary lymphoma of the central nervous system.
- •Previous radiation therapy is allowed, but it must have been limited and there must not have been total radiation from the pelvis. Patients must have recovered from the toxic effects of the treatment before being enrolled in the study (except alopecia). The previous radiotherapy treatment must be completed 30 days before being included in the study. Lesions that have been irradiated can not be included as measurable sites of the disease unless the tumor progression in these lesions has been clearly documented since the end of radiotherapy.
- •Have a second primary malignancy (except for adequately treated non-melanoma skin cancer, or another cancer that is considered cured by surgical resection or radiation). Patients who had another malignancy in the past are eligible, but have been free of disease for more than 5 years.
- •Anti-Lymphoma Therapy within the previous 3 weeks.
- •Impossibility of swallowing the pills
- •One who can not stop the use of carbamazepine, phenobarbital and phenytoin for at least 14 days before being enrolled in the study
- •Pre-treatment with enzastaurin
- •Have a serious concomitant systemic disorder, according to the researcher
- •Active infection that requires antibiotics
- •Having a serious cardiac condition in the opinion of the investigator, such as AML within the previous 6 months, angina, or heart disease as defined by NYHA class III or IV.
- •That is known to be HIV positive
- •Have an abnormal electrocardiogram including the base electrocardiogram, 12-lead ECG, with QTc interval> 430 msec in men or> 450 msec in women, or QRS duration> 100 msec.
- •Being pregnant or breastfeeding.
研究者
相似试验
进行中（未招募）
不适用
Japanese Children & Adolescents New Onset Fever & NeutropeniaCandida or Aspergillus InfectionsEUCTR2014-004910-27-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.20
进行中（未招募）
不适用
Study of CANCIDAS in Children types of ungal infectionsCandida and Aspergillus infectionsEUCTR2014-004911-35-Outside-EU/EEAMerck & Co., Inc.50
进行中（未招募）
不适用
A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, InclusiveCrohn's DiseaseEUCTR2011-003743-22-DEAstraZeneca AB110
进行中（未招募）
1 期
A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, InclusiveMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's DiseaseEUCTR2011-003743-22-ITASTRAZENECA123
进行中（未招募）
不适用
A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort™ EC as a Maintenance Treatment for Crohn’s Disease in Paediatric Subjects Aged 5 to 17 Years, InclusiveMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's DiseaseEUCTR2011-003742-40-DEAstraZeneca AB50